Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 21, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis et Medicines for Malaria Venture lancent une étude clinique en Afrique pour KAF156, un candidat-médicament novateur contre le paludisme multirésistant

Ce candidat-médicament pourrait s'avérer déterminant dans la lutte contre le paludisme en éliminant rapidement l'infection paludéenne, y compris les souches résistantes et en bloquant la...
August 21, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis und Medicines for Malaria Venture starten in Afrika eine Patientenstudie mit KAF156, einem neuartigen Wirkstoff gegen multiresistente Malaria

Der Wirkstoff führt zu rascher Parasitenfreiheit auch bei resistenten Erregerstämmen, blockiert die Übertragung der Erreger und könnte damit eine Wende im Kampf gegen Malaria herbeiführen. ...
July 25, 2017 01:15 ET | Source: Novartis Pharma AG

Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries

Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is...
July 21, 2017 07:19 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)

Recommendation based on largest trial in FLT3-mutated AML to date, showing 23% reduction in the risk of death with Rydapt treatment regimen[1] If approved, Rydapt would represent the first...
July 18, 2017 01:00 ET | Source: Novartis Pharma AG

Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products

Net sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications ...
July 18, 2017 01:00 ET | Source: Novartis Pharma AG

Les résultats du T2 confirment les prévisions de l'exercice 2017. Les très bons résultats du pipeline étayent le potentiel de plusieurs produits hautement novateurs

Chiffre d'affaires net comparable à celui du T2 de l'exercice précédent (0% tcc[1], -2% en USD), car les moteurs de croissance ont compensé l'impact des génériques de Gleevec/Glivec: Cosentyx...
July 18, 2017 01:00 ET | Source: Novartis Pharma AG

Die Ergebnisse im zweiten Quartal bestätigen die Jahresprognosen - starke Forschungs- und Entwicklungsresultate untermauern das Potenzial einiger hoch innovativer Produkte

Der Nettoumsatz liegt auf Vorjahresniveau (0% kWk[1], -2% USD), wobei die Wachstumstreiber die Einbussen durch Generika von Glivec/Gleevec wettmachen: Cosentyx (USD 490 Millionen, +90% kWk) setzt...
July 14, 2017 13:21 ET | Source: Novartis Pharma AG

Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis

5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis[1] Data planned to be presented...
July 12, 2017 17:20 ET | Source: Novartis Pharma AG

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial A Biologics License Application (BLA) for this indication is...
July 06, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis

Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx® versus Stelara® in psoriasis [1],[2] Update also includes use of Cosentyx in...